Detection of Primary Colorectal Cancer With Indium 111 Monoclonal Antibody B72.3
- 1 December 1990
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Surgery
- Vol. 125 (12) , 1601-1605
- https://doi.org/10.1001/archsurg.1990.01410240083016
Abstract
• B72.3 is a murine monoclonal antibody of the immunoglobulin subclass IgG1 directed against TAG-72, a cell surface antigen present on colorectal carcinoma cells. We investigated the utility of scanning with indium 111–labeled B72.3 in 16 patients with a high clinical suspicion of or biopsy-proven primary colorectal cancer. Each patient received 1 or 2 mg of B72.3 monoclonal antibody labeled with 152 MBq of indium 111. Patients underwent scanning 2 to 3 days and 7 days after infusion by planar and emission computed tomography. Nineteen lesions were confirmed in 12 patients. Three patients with benign polyps had true-negative monoclonal antibody scans. Indium 111–labeled imaging of B72.3 detected nine of 19 lesions. Unsuspected tumor sites were identified by monoclonal antibody scan in three patients. By detection of additional abdominal disease and extra-abdominal spread, indium 111–labeled scanning of B72.3 directly affected treatment in 18% of patients. (Arch Surg. 1990;125:1601-1605)Keywords
This publication has 6 references indexed in Scilit:
- In-111-labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma: safety, sensitivity, and preliminary clinical results.Radiology, 1990
- Colorectal carcinoma: a radiologic and clinical review.Radiology, 1987
- A critical review of the classifications and staging of colorectal cancerDiseases of the Colon & Rectum, 1983
- Enhanced Survival of Patients with Colon and Rectal Cancer is Based Upon Wide Anatomic ResectionAnnals of Surgery, 1979
- Detection and treatment of recurrent cancer of the colon and rectumThe American Journal of Surgery, 1978
- Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectumCancer, 1976